The effects of hormone replacement therapy in hypertensive women are controversial. This randomised placebo controlled trial assessed the effect of tibolone 2.5 mg on blood pressure and fasting plasma lipids in 29 hypertensive postmenopausal women over 6 months using a 2:1 randomisation to tibolone. The primary clinical end-point was mean office blood pressure. At 6 months systolic blood pressure declined by 5.30 ؎ 2.87% vs 4.94 ؎ 3.37% whilst diastolic blood pressure declined 5.38 ؎ 2.65% vs 0.85 ؎ 3.69% on tibolone and placebo respectively. These differences were not statistically significant. Triglycerides decreased by 33.3 ؎ 6.1% vs 7.6 ؎ 7.9% (P Ͻ 0.01) and
Introduction
The role of hormone replacement therapy (HRT) in women with hypertension remains controversial. Oestrogen-based HRT remains underused in these women probably because of concerns about blood pressure deterioration in younger women taking the oral contraceptive. 1 However, the potentially beneficial effects of HRT in reducing coronary heart disease (CHD) risk would suggest a role for it in the management of hypertension. 2, 3 The loss of oestrogen at the menopause appears to be associated with an overall rise in blood pressure. 4 Little information is available regarding the long-term effects of HRT in hypertensive women, but short duration studies in hypertensive women have demonstrated either a neutral or even modest hypotensive effect. [5] [6] [7] [8] [9] [10] Cyclical HRT preparations are unacceptable to most women suffering from coronary disease or hypertension. Tibolone is a novel steroid compound, which controls menopausal symptoms, 11 inhibits postmenopausal bone loss 12 and augments forearm blood flow. 13 It does not induce endometrial hyperplasia or, usually, postmenopausal bleeding. 14 We investigated the effect of introducing tibolone in women with pre-existing hypertension on both blood pressure and biochemical cardiovascular risk factors.
Materials and methods

Study design
The trial had a double-blind, randomised, placebocontrolled format. Randomisation was 2:1 in favour of tibolone to increase the probability of demonstrating a treatment effect. The study received local ethical approval and written informed consent was obtained. At two baseline visits clinical details, baseline blood pressure, quality of life parameters and fasting lipid profiles were measured. Patients were reviewed monthly for continued blood pressure assessment. Baseline biochemical investigations were repeated at the final clinical visit after 6 months treatment.
Eligibility
Eligible patients had previously diagnosed hypertension on or off treatment with antihypertensives. All had three separate standard mercury sphygmomanometer blood pressure readings greater than 160/90 mm Hg over 3 months or were taking longterm antihypertensive treatment. All were 1 or more years postmenopausal on clinical grounds. Exclusion criteria included, intrinsic renal disease, insulin-dependent diabetes or a past history of an oestrogen dependent tumour. Women who had used sex steroid compounds including oral contraception, previous HRT, progesterone, tibolone or tamoxifen within the previous 3 months were excluded.
Blood pressure measurement
Blood pressure was measured as near as possible at the same time of the same day of the week by one of two operators using the British Hypertension Society approved methods. 15 For the purposes of analysis the mean of the three recumbant blood pressure measurements was calculated. If blood pressure exceeded 210/120 mm Hg on two separate visits, the patient left the study to allow modification of medication, otherwise all concomitant antihypertensive medication was left unchanged for the duration of the study.
Plasma lipids and lipoproteins
Blood samples were drawn in the recumbant position after a 12-h fast. Samples were centrifuged immediately and stored at −70°C until subsequent analysis. Plasma lipid profiles were detained in a single batch by standard automated methods for total cholesterol, triglycerides and HDL on a Cobas Fara II analyser. Low-density lipoprotein (LDL) was calculated by the Freidewald equation if triglycerides Ͻ4.5 mmol/L. Apolipoprotein (apo) A1, A2, B, lipoprotein (a) [Lp(a)] and fibrinogen were measured by immunoturbidimetric methods on the same analyser. Lp(a) samples were pre-treated by centrifugation and lipase treatment to reduce any triglyceride interference with the assay. All methods used were validated against International Federation of Clinical Chemistry standards and had standard deviations of Ͻ2.5% for lipids, Ͻ4% for apolipoproteins, Ͻ6% for Lp(a) and Ͻ3% for fibrinogen for medium range calibrators.
Quality of life
Quality of life was recorded at baseline and at 6 months using the SF-36 General Health Questionnaire. 16 This measures eight health concepts: physical functioning, physical and emotional role limitations, bodily pain, general health, vitality, social functioning, mental health and reported health transition. In each measure, a higher score indicates a better health state.
Statistical analysis
The study was powered to detect a change in mean blood of 15 mm Hg. A 2:1 randomisation was used to increase the power to detect a treatment effect while accepting an increased risk of a type I error. In patients who dropped out of the study the blood pressure at the last visit was carried forward to successive visits. Blood pressure data were analysed on an intention-to-treat basis but percentage change in lipid values was calculated only for those patients who finished the study and were taking medication at the final visit. Data were analysed using the SPSS statistical package (version 6.0). Parametric data are displayed as mean and standard error, non-parametric data as median and range while frequency data as value and percentage. Principal analysis was performed using ANOVA for repeated measures with unpaired t-testing for individual two-way comparisons between subjects allocated to tibolone or placebo. Non-parametric data (lipoprotein (a) and triglycerides) were compared using the appropriate non-parametric test (Mann-Whitney) with contingency table testing of frequency data (Yates' continuity correction). P Ͻ 0.05 was considered statistically significant.
Results
Demographics
Major demographic features were similar in the active and placebo arms of the study ( Table 1 ). The mean age of the women was 60.1 years in the active group and 62.7 years in the placebo group. Both groups were more than 10 years after the menopause (11.5 years tibolone and 16.1 years placebo). There were non-significant statistical differences in other patient characteristics and in concomitant medications.
Blood pressure
Study blood pressure readings are recorded in Figure 1 and Table 2 . The entry mean blood pressure was 161 ± 5.2/91 ± 1.8 mm Hg in the tibolone group and 157 ± 5.4/85 ± 2.4 mm Hg in the placebo. Baseline diastolic blood pressure was slightly but significantly higher in the active treatment arm (P Ͻ 0.05) but the mean arterial pressure was not significantly different (126.0 ± 3.2 vs 121.2 ± 3.6 mm Hg). Systolic blood pressure fell by 5.2%, diastolic pressure by 3.6% and mean arterial pressure by 4.6%. After 6 months the blood pressures were 151 ± 5.5/87 ± 3.4 mm Hg in the active and 148 ± 4.1/84 ± 3.2 mm Hg in the placebo arm. Neither absolute or percentage reductions in systolic and diastolic blood pressures were significantly different at 6 months. Similarly the pulse pressure was unaffected by allocation to treatment arm.
Lipids, lipoproteins and fibrinogen
Biochemical data from the trial are presented in Table 2 and Figure 2 . Total cholesterol fell in both arms of the study with no difference between tibolone and placebo groups. The reduction in total cholesterol in the placebo group was however statistically significant (P = 0.04). LDL-cholesterol rose slightly by 1.2 ± 8.0% in the tibolone group compared with a 5.3 ± 2.5% fall on placebo. High-density lipoprotein (HDL) was significantly reduced (21.7 ± 3.8%) falling from 1.40 ± 0.1 to 1.08 ± 0.1 mmol/L with tibolone compared to a 2.4 ± 2.6% rise in those on placebo. Similarly apolipoprotein A-1 fell by 20.4 ± 3.6% compared with a 2.5 ± 2.1% rise on placebo but ApoAII levels 
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declined less than ApoAI with tibolone therapy. Triglycerides were reduced by 33.4 ± 6.1% on tibolone compared to 7.6 ± 7.9% on placebo (P Ͻ 0.05).
Fibrinogen was reduced on tibolone by 13.5 ± 6.8% but rose by 19.3 ± 15.4% on placebo (P Ͻ 0.05). Median Lp(a) rose nonsignificantly in both groups during the study but final levels were similar.
Quality of life
There were no significant differences within the tibolone and placebo groups between baseline and 6-month follow-up: There were also no significant differences between the tibolone and placebo group at baseline or 6-month follow-up.
Adverse events
Both tibolone and placebo were well tolerated. Four patients taking tibolone (22%) developed some vaginal bleeding compared with one (9%) in the placebo arm; this difference was not statistically significant. One patient in the placebo group developed a major vaginal bleed resulting in hospitalisation Journal of Human Hypertension and subsequent dilatation and curettage. Two patients (11%) in the tibolone arm and two (18%) in the placebo arm terminated the study early: two (one active and placebo) because of side effects (headache, nausea and flushing), one because of the development of an intercurrent pneumonia deemed not to be related to study medication, and one for personal reasons.
Discussion
The menopause may play a role in the acceleration of hypertension in women. A rise in diastolic blood pressure and a steepening of the time dependent rise in systolic blood pressure occur in the postmenopause. 4 Concurrently other adverse changes occur in cardiac risk factors including rises in LDL and insulin resistance, falls in HDL, and changes in fat distribution. 17 Gender protection is lost so the incidence of CHD in women equals that in men by the age of 65. 18 Hypertensive women in the Nurses Health Study had a 3.5-fold increase in risk of CHD with a 2.6-fold increase in stroke compared with nonhypertensives. 19 Despite circumstantial evidence of benefit, HRT has only rarely been prescribed in hypertensive women, possibly due to the known hypertensive effects of oestrogen seen in women on the contraceptive pill.
1 However oestrogen and progestin supplementation may be beneficial in postmenopausal women with hypertension. Oestrogen acts as a vasodilator by restoring impaired endothelial function, 20 inhibiting the vasoconstrictor actions of endothelin-l 21 and by inhibiting the influx of Ca 2+ ions into vascular smooth muscle cells. 22 In addition oestrogen reduces circulating catecholamines levels 23 and may act as an angiotensin-converting enzyme inhibitor. 24 In vivo administration of oestrogen or natural progesterone can bring about an acute drop in blood pressure. 5, 6 In hypertensive women a number of small studies have documented an antihypertensive effect. Transdermal oestradiol can reduce daytime systolic pressure, 7 achieve an absolute reduction in overall pressures 8 and restore a normal 24-h ambulatory blood pressure profile. 9 Other studies have shown no effect of oestrogens on blood pressure in the hypertensive population but a reduction in plasma renin and aldosterone levels. 10 The use of HRT alongside antihypertensive therapy can offset some of the adverse metabolic effects associated with drugs such as thiazides and beta-blockers. 25 Not all studies have shown encouraging results. A study of a retirement community in the USA found a relationship between the incidence of hypertension and both dose and duration of oestrogen use. 26 Another small sequential series noted a rise in blood pressure associated with oestrogen use that returned to normal following termination of oestrogen therapy. 27 The PEPI study in normotensive women showed that oestrogen plus various progestins did not alter blood pressure significantly over a 3-year period. 2 Tibolone is a synthetic steroid with the unusual property of differential metabolism in different organs. Hence it exerts a progesterone-like inhibitory effect on breast 28 and uterine tissue 29 and
Journal of Human Hypertension relieves menopausal symptoms 11 while preventing bone loss 12 much like oestrogen. Tibolone augments forearm 11 and aortic blood flow, 30 and alters aortic distensibility, 31 which suggest it may reduce blood pressure. It has also been reported to reduce myocardial ischaemia in women with angina. 32 Furthermore in an atherosclerotic rabbit model tibolone significantly reduced the development of new atherosclerotic plaque. 33 It has androgenic effects on plasma lipids especially in reducing HDL. This study shows tibolone has no differential effect on HDL-cholesterol uptake and transfer as HDL and apoA1 levels were reduced in parallel. The effects of tibolone on HDL affect apoA1 more than apoA2, implying deleterious effects on reverse cholesterol transport is HDL:A1 but not HDL:A1:A2 dependent. It also may have differential effects on apoA gene expression as these genes are usually co-ordinately regulated. Alterations in lipid risk factors for CHD such as triglycerides and Lp(a) may outweigh the effects of tibolone on HDL. 34 -36 It is of note that cholesterol levels fell significantly in the placebo group. This is difficult to understand as no specific dietary advice was given and lipidlowering therapy was held as a constant throughout the study. Presumably partaking in a clinical study caused subjects to have heightened awareness of cardiac risk factors and pay more attention to diet and lifestyle issues.
This randomised placebo-controlled trial demonstrated no clinically significant alteration in blood pressure in hypertensive women taking tibolone for 6 months. The study, though small, was powered to detect a clinically relevant change in blood pressure that might affect clinical decision-making (15 mm Hg). These results support the findings of a large observational study of tibolone which found no rise in blood pressure in 75 hypertensive menopausal women over 14 months. 37 The effects of tibolone on lipids were similar to those previously described with a 20-25% fall in HDL. The adverse effect on the LDL:HDL, apoB: apoA1 and apoB:(apoA1-A2) ratios imply that tibolone interfered with reverse cholesterol transport and for this reason may be deleterious. However, the 33% reduction in triglycerides and 19% reduction in fibrinogen may counterbalance this effect. In the most current model of cardiac risk derived from the Framingham study, incorporating TC, HDL-C and other risk factors, tibolone increased cardiac risk by about 18% but this was not statistically significant and in this population represented a rise in absolute risk of 2.6%. 38 A fall in Lp(a) with tibolone has been noted but this was not reproduced here. 35 The measurement of Lp(a) is difficult to standardise and subject to wide variation so both studies are likely to be underpowered. Larger scale studies of the effects of tibolone on Lp(a) are required. Tibolone was well tolerated and did not significantly effect the quality of life.
Conclusions
Tibolone at a dose of 2.5 mg is safe to use in women with treated or untreated hypertension, with mini-mal effects on blood pressure. The balance between its adverse effects on HDL and the beneficial effects on triglycerides and fibrinogen should be the subject of further study in women at risk of CHD.
